RO-7268489 NCT07282574 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2028-05-30

Primary-completion proxy

Executive view

NCT07282574 evaluates RO-7268489 in Multiple Sclerosis, Chronic Progressive. The disclosed sponsor is Roche Holding AG, the design is Interventional, and the geographic footprint is New Zealand, Hungary, Turkey, Poland, Brazil, United Kingdom, Italy, France, Australia, Portugal, Germany, Spain. The first listed primary endpoint is Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12), assessed over Up to approximately 110 weeks.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07282574 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Sclerosis, Chronic Progressive landscape. Drug & Asset MCP drug_fetch was queried for RO-7268489, while Company & Deal Intelligence MCP organization_fetch was queried for Roche Holding AG.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07282574	RO-7268489	Phase 2 / Recruiting	Roche Holding AG	New Zealand, Hungary, Turkey, Poland, Brazil, United Kingdom, Italy, France, Australia, Portugal, Germany, Spain	Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at L… Up to approximately 110 weeks	2028-05-30
NCT07325292	Frexalimab	Phase 3 / Recruiting	Sanofi	Belgium, United States, Japan, China, Brazil, Italy, Spain	Area under the curve over the interval W20 to W24(part A) Until Week 24	2027-07-15
NCT07321093	Ocrelizumab Biosimilar(Biocad)	Phase 3 / Recruiting	Biocad CJSC	Russia	Total number of T1 gadolinium-enhancing (Gd+) lesions up to Week 24. up to Week 24	2028-12-01
NCT07303790	GC-012F	Early Phase 1 / Recruiting	Huazhong University of Science Tongji Hospital, Tongji Medical College	China	Dose-Limiting Toxicity (DLT) Rate 28 days	2027-01-20
NCT07299019	Orelabrutinib	Phase 3 / Recruiting	Zenas BioPharma LLC.	United States, Hungary, Czechia, Poland, Italy, Serbia, Lithuania, Bulgaria, Estonia, Croatia	Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks Up to approximately 120 weeks	2030-06-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07282574 is a Phase 2, recruiting study with not reported planned participants. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment.

The primary endpoint is “Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)” over “Up to approximately 110 weeks.” The retrieved endpoint description is: Time from randomization to the first occurrence of cCDP12 according to at least one of the following 3 criteria: 1. 12-week confirmed disability progression (CDP12) 2. 12-week confirmed increase in Timed 25-Foot Walk Test (T25FWT) or 3. 12-week confirmed increase in 9-Hole Peg Test (9-HPT) The EDSS is a disability scale is based on a standard neurological examination that ranges in 0.5-point steps from 0 (normal) - 10 (death). T25FWT=time taken to walk 25 feet, typically measured in seconds. The longer it takes to walk, the higher score, which indicates deterioration. Lower times indicate better performance and….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Ocrelizumab as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Multiple Sclerosis, Chronic Progressive. These records do not establish direct evidence for NCT07282574 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

RO-7268489 is indexed as Small molecule drug with MAGL biology and a global stage of Phase 2. The asset profile lists Roche Holding AG as an originator or developer.

Roche Holding AG is indexed in an unreported country with the website http://www.roche.com. Roche is a pharmaceutical and diagnostics company that offers medicines and diagnostic tests for various medical conditions and diseases. The record lists 156 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether RO-7268489 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07282574
Protocol source: https://clinicaltrials.gov/study/NCT07282574
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

RO-7268489 in Multiple Sclerosis, Chronic Progressive is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12) and 2028-05-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP